ストックスクリーナーアプリを入手
54.43
7.13%
-4.18
アフターアワーズ：
54.78
0.35
+0.64%
Sarepta Therapeutics Inc (SRPT) 最新ニュース
Sarepta Therapeutics Temporarily Halts Three Clinical Studies Of Elevidys: Retail Is Dull While Stock Drops - Asianet Newsable
Barclays Reiterates Overweight Rating on Sarepta Therapeutics (SRPT) - StreetInsider
Trial monitors recommend Elevidys studies continue; Novartis kidney drug approved - BioPharma Dive
Sarepta falls after halting three studies of Duchenne gene therapy - TradingView
Sarepta Therapeutics Stock Falls as Some Trials Halted After Patient Death - Investopedia
Sarepta indicates it’s safe to continue Elevidys dosing in Europe; Epsilogen buys TigaTx - Endpoints News
Sarepta (SRPT) and Roche to Submit Data to EU for Lifting Clinical Hold - GuruFocus
Sarepta Says EU Regulators Temporarily Halt Enrollment, Dosing in Elevidys Trials - MarketScreener
Sarepta halts three studies testing gene therapy for muscle disorder - MarketScreener
Sarepta, Roche seek to resume Elevidys trials (SRPT:NASDAQ) - Seeking Alpha
Sarepta price target lowered to $183 from $202 at Needham - Yahoo Finance
Sarepta gene therapy trials to resume after safety review - Investing.com
Sarepta Therapeutics Provides Update On Elevidys - MarketScreener
Sarepta's ELEVIDYS Trials Paused: DMC Confirms Positive Benefit-Risk Profile - Stock Titan
SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy - Zacks Investment Research
Arrowhead and Sarepta Forge $11.38 Billion Partnership to Advance Neuromuscular Therapies" - openPR.com
Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Upgraded by HC Wainwright - Defense World
Cell and Gene Therapy Market: The Groundbreaking Treatments - openPR.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Shareholders to Connect - ACCESS Newswire
Sector Update: Health Care Stocks Decline Late Afternoon - MarketScreener
Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death - Benzinga
Sarepta Therapeutics Inc (SRPT) Recovers -2.75% From Low: Are We There Yet? - stocksregister.com
Sector Update: Health Care - MarketScreener
European Medicines Agency Requests Pause on Trials for Sarepta’s DMD Gene Therapy Elevidys - CGTLive®
Sarepta Shares Fall After EMA Reportedly Places Hold on Elevidys Trial Enrollment for Duchenne Muscular Dystrophy - MarketScreener
Roche halts testing of Sarepta Duchenne gene therapy in Europe - BioPharma Dive
Smart Money Is Betting Big In SRPT Options - Benzinga
Sarepta stock plunges to 52-week low, touches $57.22 - Investing.com
Sarepta stock down on EU clinical hold (update) (SRPT:NASDAQ) - Seeking Alpha
Apple To $250? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Deutsche Bank Adjusts Sarepta Therapeutics Price Target to $70 From $99, Maintains Hold Rating - MarketScreener
Multiple studies of Sarepta's DMD therapy halted after death - pharmaphorum
Sarepta Therapeutics (SRPT) Faces EMA Hold on Gene Therapy Trials - GuruFocus
Needham cuts Sarepta stock target to $183, maintains buy By Investing.com - Investing.com UK
Deep Dive Into Sarepta Therapeutics Stock: Analyst Perspectives (18 Ratings) - Benzinga
EMA halts Sarepta’s DMD gene therapy trial after patient death - The Pharma Letter
Commonwealth Equity Services LLC Buys 1,151 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
HC Wainwright & Co. Upgrades Sarepta Therapeutics (BMV:SRPT) - Nasdaq
Could The Market Be Wrong About Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Its Attractive Financial Prospects? - simplywall.st
Sarepta Therapeutics (SRPT) Upgraded to Neutral as 1Q25 Earnings Anticipated - GuruFocus
Sarepta Therapeutics Shares Rise After HC Wainwright Upgrade - MarketScreener
HC Wainwright & Co. Upgrades Sarepta Therapeutics (LSE:0L35) - Nasdaq
Sarepta stock upgraded at H.C. Wainwright (SRPT:NASDAQ) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sarepta Therapeutics, Inc. (SRPT) And Encourages Shareholders to Reach Out - markets.businessinsider.com
HC Wainwright & Co. Upgrades Sarepta Therapeutics (SRPT) - Nasdaq
Sarepta stock rating raised to neutral by H.C. Wainwright - Investing.com
HC Wainwright Upgrades Sarepta Therapeutics to Neutral From Sell, Price Target is $75 - MarketScreener
Sarepta price target lowered to $179 from $210 at BofA - Yahoo Finance
Best- and Worst-Performing Stocks of Q1 2025 - Morningstar
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Shareholders to Learn More About the Investigation - markets.businessinsider.com
Sarepta Therapeutics (NASDAQ:SRPT) Lowered to “Sector Perform” Rating by Royal Bank of Canada - Defense World
RBC Capital Downgrades Sarepta Therapeutics (LSE:0L35) - Nasdaq
RBC Capital Downgrades Sarepta Therapeutics (SRPT) - MSN
Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bluefield Daily Telegraph
Top vaccine official’s ouster sends biotech stocks tumbling - The Boston Globe
Sarepta Therapeutics (SRPT) Faces Uncertainty Amid FDA Departure and Elevidys Concerns - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc.SRPT - PR Newswire
Why Sarepta Therapeutics (SRPT) Stock Is Nosediving - Yahoo Finance
Moderna Stock Sinks After Top FDA Official Resigns; Sarepta Gets Hit, Too. - MSN
RBC Capital Downgrades Sarepta Therapeutics (BMV:SRPT) - Nasdaq
Sarepta downgraded at RBC Capital on gene therapy concerns (SRPT:NASDAQ) - Seeking Alpha
Fiery Resignation of Top FDA Official Sparks Biotech Stock Selloff - Barron's
Sarepta Craters After RBC’s 45% Price Target Cut - Wall Street Pit
Drugmakers tumble on reports FDA's top vaccine regulator set to leave - MarketScreener
A recent gene therapy death shines a light on AAV safety - PharmaVoice
Biotech stocks tumble on reports FDA's top vaccine regulator to leave - MarketScreener
RBC Downgrades Sarepta Therapeutics to Sector Perform From Outperform, Adjusts PT to $87 From $161 - MarketScreener
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Investors to Learn More About the Investigation - markets.businessinsider.com
10.70%
大文字化:
|
ボリューム (24 時間):